Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded down $0.39 on Tuesday, reaching $57.90. The stock had a trading volume of 1,656,112 shares, compared to its average volume of 1,276,348. Halozyme Therapeutics has a 12 month low of $35.50 and a 12 month high of $65.53. The firm has a market capitalization of $7.37 billion, a price-to-earnings ratio of 19.17, a P/E/G ratio of 0.44 and a beta of 1.25. The firm’s 50-day moving average is $52.69 and its two-hundred day moving average is $54.51. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.